ClinicalTrials.gg
CompletedNCT01619332Updated Dec 17, 2020

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

A Phase 1/2 interventional study of Placebo and Sitagliptin in Type II Diabetes, sponsored by Novartis Pharmaceuticals. Completed at 6 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-17.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
220
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
67th of 197
220 · median 102
Started
2012
with 15 others
Phase 1/2
Only one
of the 198
Registered
120th of 198
by date

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 67th largest by enrollment of the 197 interventional ones that give a count, is one of 16 that started in 2012, is the only one in phase 1/2, and was the 120th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study is a three part study to assess the safety and efficacy of LEZ763 on normal healthy volunteers and patients with Type 2 Diabetes.

03

Conditions studied

  • Type II Diabetes

Keywords

  • Healthy volunteers,
  • Diabetes
  • Glucose
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All subjects: (suggest this will reduce duplication)
  • Male or female aged 18-65 yr,
  • Subjects must weigh at least 50 kg to participate in the study. (BMI) must be within the range of 18-37 kg/m2 (inclusive
  • Only females or female subjects who report surgical sterilization (women without child bearing potential) will be allowed in this study.
  • Subjects with stable conventional sleep-wake cycle

Normal Healthy Volunteers

  • Healthy male or female subjects,
  • must be in good health (as determined by past medical history, physical examination, vital signs, , and laboratory tests at Screening).

Type II Diabetic Patients

  • Type 2 diabetes diagnosed by American Diabetes Association criteria for at least 3 months prior to screening.
  • Patients either drug naïve or on stable dose of metformin (stable dose for at least 4 weeks prior to Screening). The metformin dose should remain constant during the course of the study.
  • 6.5 to 9.5 % inclusive at screening

Exclusion criteria

Exclusion criteria:

All subjects:

  • Smokers (use of tobacco products in the previous 3 months).
  • Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation.
  • Significant illness within two weeks prior to dosing.
  • Have (or have history of) drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening or baseline evaluations

Normal Healthy Volunteers

  • History of diabetes, or adrenal disorders.

Type II Diabetic Patients

  • Type 1 diabetes mellitus; positive anti-GAD antibodies; acquired or secondary forms of diabetes such as those resulting from pancreatic surgery/injury, cystic fibrosis related diabetes
  • Evidence of diabetic complications (such nephropathy, retinopathy, neuropathy) Other protocol defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    LEZ763

    Part I- Healthy volunteers enrolled into 6 single-ascending dose cohorts Part II- Healthy volunteers enrolled into 5 multiple-ascending dose cohorts. Part III- LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner

    Drug: LEZ763

  • Placebo comparator
    Placebo

    Part I : Healthy volunteers enrolled in 6 single ascending dose cohorts to receive matching placebo of LEZ763. Part II: Healthy volunteers enrolled in 5 multiple ascending dose cohorts to receive matching placebo of LEZ763. Part III- Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner

    Drug: Placebo

  • Active comparator
    Sitagliptin

    Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner

    Drug: Sitagliptin

Interventions

  • DrugPlacebo

    Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner

  • Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner

  • DrugLEZ763

    LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner

06

What researchers measure

Primary outcomes

  1. Number of Patients with adverse events, serious adverse events and death

    An adverse event is the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. Adverse events will also be determined on the basis of clinical laboratory assessments, electrocardiographic evaluations and vital signs determinations.

    Time frame: Day 28

  2. Pharmacokinetics of LEZ763 (Part I): area under the plasma concentration-time curve from time zero to infinity (AUCinf)

    Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose

    Time frame: pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4

  3. Pharmacokinetics of LEZ763 (Part I): area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)

    Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose

    Time frame: pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4

  4. Pharmacokinetics of LEZ763 (Part I): Terminal elimination half-life (T1/2)

    Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose

    Time frame: pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4

  5. Pharmacokinetics of LEZ763 (Part I): Apparent systemic (or total body) clearance from plasma following extravascular administration (CL/F)

    Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose

    Time frame: pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4

  6. Pharmacokinetics of LEZ763 (Part I) : Observed maximum plasma concentration (Cmax) following drug administration

    Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses

    Time frame: pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4

  7. Pharmacokinetics of LEZ763 (Part I): time to reach the maximum concentration after drug administration (Tmax)

    Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose

    Time frame: pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4

  8. Pharmacokinetics of LEZ763 (Part II) : Observed maximum plasma concentration (Cmax) following drug administration

    Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses

    Time frame: pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 10

  9. Pharmacokinetics of LEZ763 (Part II): time to reach the maximum concentration after drug administration (Tmax)

    Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses

    Time frame: pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 10

  10. Pharmacokinetics of LEZ763 (Part II): Accumulation ratio(Racc)

    Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses

    Time frame: pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27

  11. Pharmacokinetics of LEZ763 (Part III) : Observed maximum plasma concentration (Cmax) following drug administration

    Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses

    Time frame: pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27

  12. Pharmacokinetics of LEZ763 (Part III): time to reach the maximum concentration after drug administration (Tmax)

    Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses

    Time frame: pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27

  13. Pharmacokinetics of LEZ763 (Part III): Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau (AUCtau)

    Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses

    Time frame: pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27

  14. Pharmacokinetics of LEZ763 (Part III): Accumulation ratio(Racc)

    Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses

    Time frame: pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27

  15. Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Observed maximum plasma concentration (Cmax) following drug administration

    Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses

    Time frame: pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day 28

  16. Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau (AUCtau)

    Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses

    Time frame: pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day 28

  17. Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Time to reach the maximum concentration after drug administration (Tmax)

    Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses

    Time frame: pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day 28

  18. Area under the effect curve (AUC0-4h) over the 4-hour post-dose period to measure glucose response following a standard mixed meal test

    Time frame: 4 hour post-dose Day 27

Secondary outcomes

  1. Area under the serum Glucagon-like-peptide 1 (GLP-1) curve (AUC0-24 hours)

    GLP-1 Biomarker measures will be evaluated at pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose

    Time frame: Pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day -1, Day 1, Day 27, and Day 28

  2. 2-hour value of post-prandial glucose

    Time frame: Day 1 of Part I, Day 1 and day 10 of Part II

  3. Change from baseline in Fasting C-peptide at Day 27 (Part III)

    Time frame: Baseline, Day 27

  4. Change from baseline in Fasting Insulin at Day 27 (Part III)

    Time frame: Baseline , Day 27

  5. Change from baseline in fasting plasma glucose at Day 27 (Part III)

    Time frame: Baseline , Day 27

  6. Change From Baseline in peak glucose level following meal Test at Day 27 (Part III)

    Time frame: Baseline , Day 27

  7. Peak effect (Emax) on postprandial GLP-1 (Part III)

    Time frame: Baseline , Day 27

  8. Change from baseline in Peptide YY (PYY) (Part III)

    Time frame: Baseline , Day 27

  9. Change from baseine in Gastric inhibit polypeptide (GIP) (Part III)

    Time frame: Baseline , Day 27

07

Study locations

6 sites
  • Novartis Investigative Site
    Chula Vista, California 91910, United States
  • Novartis Investigative Site
    Miami, Florida 33126, United States
  • Novartis Investigative Site
    Orlando, Florida 32809, United States
  • Novartis Investigative Site
    Cincinnati, Ohio 45227, United States
  • Novartis Investigative Site
    Knoxville, Tennessee 37920, United States
  • Novartis Investigative Site
    San Antonio, Texas 78209, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2012
First posted
Jun 14, 2012
Start
Mar 2012
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Results delay requested
Mar 30, 2016
Last update
Dec 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01619332
Responsible party
Sponsor
First posted
Jun 14, 2012
Start date
Mar 2012
Primary completion
Sep 2013
Completion
Sep 2013
Last update
Dec 17, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion